SEAGEN INC. drugs
4 results
Adcetris (brentuximab vedotin)
(brentuximab vedotin)SEAGEN INC.
Usage: ADCETRIS is indicated for treating previously untreated or relapsed Classical Hodgkin Lymphoma (cHL), Systemic Anaplastic Large Cell Lymphoma (sALCL), and relapsed or refractory Large B-Cell Lymphoma (LBCL) in adults, often in combination with chemotherapy. It is also approved for pediatric high-risk cHL.
Padcev (enfortumab vedotin)
(ENFORTUMAB VEDOTIN)SEAGEN INC.
Usage: PADCEV® is indicated for adult patients with locally advanced or metastatic urothelial cancer. It can be used in combination with pembrolizumab or as a single agent for patients who have received prior PD-1 or PD-L1 inhibitors and platinum chemotherapy, or who are ineligible for cisplatin-based therapy.
Tivdak (tisotumab vedotin)
(tisotumab vedotin)Seagen Inc.
Usage: TIVDAK® is indicated for adult patients with recurrent or metastatic cervical cancer that has progressed after chemotherapy.
Tukysa (tucatinib)
(tucatinib)SEAGEN INC.
Usage: TUKYSA is indicated for adult patients with advanced unresectable or metastatic HER2-positive breast cancer when used with trastuzumab and capecitabine, as well as for RAS wild-type, HER2-positive metastatic colorectal cancer in combination with trastuzumab, after prior chemotherapy.